Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Common Equity (2022 - 2023)

Bluejay Diagnostics (BJDX) has disclosed Common Equity for 2 consecutive years, with $5.2 million as the latest value for Q3 2023.

  • Quarterly Common Equity fell 62.25% to $5.2 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Sep 2023, down 62.25% year-over-year, with the annual reading at $11.5 million for FY2022, N/A changed from the prior year.
  • Common Equity hit $5.2 million in Q3 2023 for Bluejay Diagnostics, down from $6.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $18.5 million in Q1 2022 to a low of $5.2 million in Q3 2023.